Canada markets closed

NervGen Pharma Corp. (NGEN.V)

TSXV - TSXV Real Time Price. Currency in CAD
Add to watchlist
2.0600-0.0300 (-1.44%)
At close: 03:59PM EDT
Full screen
Previous Close2.0900
Open2.0600
Bid2.0600 x 0
Ask2.0900 x 0
Day's Range2.0200 - 2.1000
52 Week Range1.5800 - 3.9800
Volume30,045
Avg. Volume105,670
Market Cap144.051M
Beta (5Y Monthly)1.46
PE Ratio (TTM)N/A
EPS (TTM)-0.3800
Earnings DateAug 07, 2024 - Aug 12, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.50
  • Newsfile

    NervGen Pharma to Present Two Posters at the American Spinal Injury Association 51st Annual Scientific Meeting

    Vancouver, British Columbia--(Newsfile Corp. - May 17, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF), a clinical-stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced today that Daniel Mikol, MD, Ph.D., Chief Medical Officer, will be presenting two posters at the upcoming American Spinal Injury Association (ASIA) 51st Annual Scientific Meeting being held on May 20-23, 2024, in San Juan, Puerto Rico. ASIA gathers resear

  • Newsfile

    NervGen Pharma Reports Q1 2024 Financial Results and Operational Updates

    Target for completing enrollment of the chronic cohort in the Phase 1b/2a clinical trial moved to Q3 2024Subacute cohort protocol being amended to enhance feasibility and lessen burden on participantsCA$23 million bought deal financing completed in March 2024 provides expected cash runway through Q3 2025 Vancouver, British Columbia--(Newsfile Corp. - May 16, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF), a clinical-stage biotech company dedicated to developing innovative solutions for

  • Newsfile

    NervGen Files Management Information Circular and Announces Board of Directors Transition

    Bill Radvak to transition to Board Advisor following decision to not stand for re-election to NervGen's Board of DirectorsAnnual General Meeting of Shareholders to be held on June 4, 2024Vancouver, British Columbia--(Newsfile Corp. - May 7, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical-stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced that its Management Information Circular